FATE
Fate Therapeutics, Inc. NASDAQ Listed Oct 1, 2013$2.44
Mkt Cap $283.7M
52w Low $0.91
98.7% of range
52w High $2.46
50d MA $1.33
200d MA $1.20
P/E (TTM)
-1.3x
EV/EBITDA
-1.2x
P/B
0.9x
Debt/Equity
0.4x
ROE
-65.8%
P/FCF
-1.0x
RSI (14)
—
ATR (14)
—
Beta
2.24
50d MA
$1.33
200d MA
$1.20
Avg Volume
1.5M
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
12278 Scripps Summit Drive · San Diego, CA 92131 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -0.27 | -0.27 | +0.0% | 1.56 | -0.6% | -5.1% | -3.8% | -12.2% | -7.1% | -11.5% | — |
| Nov 13, 2025 | AMC | -0.29 | -0.27 | +6.9% | 0.99 | -0.7% | -2.9% | -1.9% | +2.8% | +5.8% | +0.8% | — |
| Aug 12, 2025 | AMC | -0.35 | -0.29 | +17.1% | 0.94 | +1.5% | +20.7% | +14.3% | +16.4% | +28.2% | +21.8% | — |
| May 13, 2025 | AMC | -0.39 | -0.32 | +17.9% | 1.00 | +5.0% | -4.0% | +1.0% | +7.0% | +22.0% | +25.0% | — |
| Mar 5, 2025 | AMC | -0.44 | -0.31 | +29.5% | 0.91 | +0.5% | +14.9% | +11.6% | +2.4% | +6.1% | +11.6% | — |
| Nov 12, 2024 | AMC | -0.42 | -0.40 | +4.8% | 2.38 | +2.9% | -8.8% | -12.6% | -15.1% | -4.6% | -8.4% | — |
| Aug 13, 2024 | AMC | -0.47 | -0.33 | +29.8% | 3.34 | +1.2% | -2.1% | +1.5% | +1.8% | +8.7% | +9.9% | — |
| May 9, 2024 | AMC | -0.47 | -0.47 | +0.0% | 3.90 | -1.3% | +4.6% | +6.4% | +8.2% | +8.7% | +6.2% | — |
| Feb 26, 2024 | AMC | -0.57 | -0.45 | +21.1% | 6.95 | +8.8% | +7.3% | +2.7% | +2.0% | +11.4% | +1.9% | — |
| Nov 8, 2023 | AMC | -0.59 | -0.46 | +22.0% | 2.33 | +3.0% | -8.6% | -11.6% | -14.6% | -0.9% | +6.4% | — |
| Aug 8, 2023 | AMC | -0.58 | -0.54 | +6.9% | 3.53 | -0.8% | -3.7% | -7.6% | -12.5% | -14.4% | -17.0% | — |
| May 3, 2023 | AMC | -0.55 | -0.19 | +65.5% | 6.32 | -5.1% | -2.4% | -10.1% | -13.8% | -14.7% | -15.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 31 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $1.29 | $1.40 | +8.5% | +4.7% | -2.3% | -7.8% | -15.5% | -19.4% |
| Oct 27 | Wedbush | Upgrade | Neutral → Outperform | — | $1.65 | $1.75 | +6.1% | -6.1% | -9.7% | -18.8% | -21.8% | -18.2% |
| Oct 27 | Needham | Maintains | Hold → Hold | — | $1.65 | $1.75 | +6.1% | -6.1% | -9.7% | -18.8% | -21.8% | -18.2% |
| Aug 13 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $0.94 | $0.95 | +1.5% | +20.7% | +14.3% | +16.4% | +28.2% | +21.8% |
| Jun 12 | Needham | Maintains | Hold → Hold | — | $1.55 | $1.50 | -3.2% | -9.7% | -18.1% | -20.0% | -22.6% | -21.9% |
| May 14 | Baird | Maintains | Neutral → Neutral | — | $1.00 | $1.05 | +5.0% | -4.0% | +1.0% | +7.0% | +22.0% | +25.0% |
| May 14 | Needham | Maintains | Hold → Hold | — | $1.00 | $1.05 | +5.0% | -4.0% | +1.0% | +7.0% | +22.0% | +25.0% |
| May 14 | Barclays | Maintains | Overweight → Overweight | — | $1.00 | $1.05 | +5.0% | -4.0% | +1.0% | +7.0% | +22.0% | +25.0% |
| Mar 6 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $0.91 | $0.91 | +0.5% | +14.9% | +11.6% | +2.4% | +6.1% | +11.6% |
| Mar 6 | Wedbush | Maintains | Neutral → Neutral | — | $0.91 | $0.91 | +0.5% | +14.9% | +11.6% | +2.4% | +6.1% | +11.6% |
| Mar 6 | Needham | Maintains | Hold → Hold | — | $0.91 | $0.91 | +0.5% | +14.9% | +11.6% | +2.4% | +6.1% | +11.6% |
| Mar 6 | Stifel | Maintains | Hold → Hold | — | $0.91 | $0.91 | +0.5% | +14.9% | +11.6% | +2.4% | +6.1% | +11.6% |
| Aug 22 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.91 | $3.96 | +1.3% | -3.6% | -1.8% | -0.8% | -8.2% | -10.2% |
| Jun 17 | Piper Sandler | Upgrade | Neutral → Overweight | — | $3.61 | $3.93 | +8.9% | -1.1% | -5.5% | -0.6% | +4.2% | +6.4% |
| May 16 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $4.24 | $4.26 | +0.5% | -2.4% | -8.0% | -7.8% | -12.7% | -13.9% |
| May 10 | Wedbush | Maintains | Neutral → Neutral | — | $3.90 | $3.85 | -1.3% | +4.6% | +6.4% | +8.2% | +8.7% | +6.2% |
| May 10 | BMO Capital | Maintains | Market Perform → Market Perform | — | $3.90 | $3.85 | -1.3% | +4.6% | +6.4% | +8.2% | +8.7% | +6.2% |
| May 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.90 | $3.85 | -1.3% | +4.6% | +6.4% | +8.2% | +8.7% | +6.2% |
| May 10 | Piper Sandler | Maintains | Neutral → Neutral | — | $3.90 | $3.85 | -1.3% | +4.6% | +6.4% | +8.2% | +8.7% | +6.2% |
| May 6 | Wedbush | Maintains | Neutral → Neutral | — | $4.06 | $4.08 | +0.5% | +3.9% | -4.4% | -8.9% | -3.9% | +0.5% |
| Apr 23 | Wedbush | Maintains | Neutral → Neutral | — | $4.78 | $4.79 | +0.2% | -5.0% | -10.0% | -19.0% | -20.5% | -15.5% |
| Mar 28 | BofA Securities | Maintains | Underperform → Underperform | — | $7.34 | $7.27 | -1.0% | +0.0% | -3.5% | -7.4% | -4.5% | -5.0% |
| Mar 19 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $7.04 | $6.83 | -3.0% | -0.6% | +5.5% | +5.5% | -6.1% | -2.4% |
| Feb 27 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $6.95 | $7.56 | +8.8% | +7.3% | +2.7% | +2.0% | +11.4% | +1.9% |
| Feb 27 | BMO Capital | Maintains | Market Perform → Market Perform | — | $6.95 | $7.56 | +8.8% | +7.3% | +2.7% | +2.0% | +11.4% | +1.9% |
| Feb 27 | Wedbush | Maintains | Neutral → Neutral | — | $6.95 | $7.56 | +8.8% | +7.3% | +2.7% | +2.0% | +11.4% | +1.9% |
| Feb 27 | Barclays | Maintains | Overweight → Overweight | — | $6.95 | $7.56 | +8.8% | +7.3% | +2.7% | +2.0% | +11.4% | +1.9% |
| Feb 27 | Oppenheimer | Maintains | Perform → Perform | — | $6.95 | $7.56 | +8.8% | +7.3% | +2.7% | +2.0% | +11.4% | +1.9% |
| Nov 20 | Mizuho | Maintains | Buy → Buy | — | $2.43 | $2.44 | +0.4% | +7.0% | +0.8% | -1.6% | -2.9% | -6.2% |
| Nov 13 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.06 | $2.01 | -2.4% | -3.4% | +12.1% | +20.4% | +15.5% | +18.0% |
| Nov 9 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $2.33 | $2.40 | +3.0% | -8.6% | -11.6% | -14.6% | -0.9% | +6.4% |
| Nov 9 | BMO Capital | Maintains | Market Perform → Market Perform | — | $2.33 | $2.40 | +3.0% | -8.6% | -11.6% | -14.6% | -0.9% | +6.4% |
| Nov 9 | Wedbush | Maintains | Neutral → Neutral | — | $2.33 | $2.40 | +3.0% | -8.6% | -11.6% | -14.6% | -0.9% | +6.4% |
| Sep 7 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $2.60 | $2.55 | -1.9% | -5.0% | -4.6% | -6.2% | -2.3% | -8.1% |
| Aug 16 | Truist | Maintains | Hold → Hold | — | $2.93 | $2.90 | -1.0% | -4.8% | -5.1% | -5.1% | -6.8% | -9.2% |
| Aug 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $3.40 | $3.37 | -0.9% | -4.1% | -9.1% | -11.2% | -13.8% | -17.9% |
| Aug 10 | Barclays | Maintains | Overweight → Overweight | — | $3.40 | $3.37 | -0.9% | -4.1% | -9.1% | -11.2% | -13.8% | -17.9% |
| Aug 9 | BMO Capital | Maintains | Market Perform → Market Perform | — | $3.53 | $3.50 | -0.8% | -3.7% | -7.6% | -12.5% | -14.4% | -17.0% |
| Aug 9 | EF Hutton | Maintains | Buy → Buy | — | $3.53 | $3.50 | -0.8% | -3.7% | -7.6% | -12.5% | -14.4% | -17.0% |
| May 5 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $6.17 | $6.28 | +1.8% | -7.9% | -11.7% | -12.6% | -13.5% | -14.7% |
| May 4 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $6.32 | $6.00 | -5.1% | -2.4% | -10.1% | -13.8% | -14.7% | -15.5% |
| May 4 | Stifel | Maintains | Hold → Hold | — | $6.32 | $6.00 | -5.1% | -2.4% | -10.1% | -13.8% | -14.7% | -15.5% |
| Mar 2 | Citigroup | Maintains | Buy → Buy | — | $6.09 | $6.10 | +0.2% | +0.0% | +0.3% | -4.4% | -6.7% | -7.7% |
| Mar 1 | EF Hutton | Maintains | Buy → Buy | — | $6.12 | $6.16 | +0.7% | -0.5% | -0.5% | -0.2% | -4.9% | -7.2% |
| Jan 24 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $5.55 | $5.42 | -2.3% | -2.2% | -2.7% | -4.5% | +6.7% | +3.2% |
| Jan 9 | Goldman Sachs | Maintains | Sell → Sell | — | $4.24 | $4.32 | +1.9% | +24.3% | +29.5% | +34.9% | +38.2% | +27.4% |
| Jan 6 | Cowen & Co. | Downgrade | Outperform → Market Perform | — | $11.00 | $4.38 | -60.2% | -61.5% | -52.1% | -50.1% | -48.0% | -46.7% |
| Jan 6 | BMO Capital | Downgrade | Outperform → Market Perform | — | $11.00 | $4.38 | -60.2% | -61.5% | -52.1% | -50.1% | -48.0% | -46.7% |
| Jan 6 | Stifel | Downgrade | Buy → Hold | — | $11.00 | $4.38 | -60.2% | -61.5% | -52.1% | -50.1% | -48.0% | -46.7% |
| Jan 6 | BofA Securities | Downgrade | Buy → Underperform | — | $11.00 | $4.38 | -60.2% | -61.5% | -52.1% | -50.1% | -48.0% | -46.7% |
No insider trades available.
Data updated apr 25, 2026 8:26am
· Source: massive.com